Clinical Trial

Allogeneic Wharton Jelly Mesenchymal Stromal Cell (WJMSC) for Treatment of Autism

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated January 24, 2025 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
Autism spectrum disorders (ASDs) are characterized by core domains: persistent deficits in social communication and interaction; restricted, repetitive patterns of behavior, interests, or activities.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-02-27.
Trial Details
NCT Number NCT06293950
Lead Sponsor University of Jordan
Conditions Autism
Enrollment 14 participants
Start Date 2022-03-09
Primary Completion 2026-06 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2025-01-24